| Literature DB >> 17176467 |
Qingmin Wu1, Jianwu Pei, Carol Turse, Thomas A Ficht.
Abstract
BACKGROUND: Random gene inactivation used to identify cellular functions associated with virulence and survival of Brucella spp has relied heavily upon the use of the transposon Tn5 that integrates at G/C base pairs. Transposons of the mariner family do not require species-specific host factors for efficient transposition, integrate nonspecifically at T/A base pairs, and, at a minimum, provide an alternative approach for gene discovery. In this study, plasmid vector pSC189, containing both the hyperactive transposase C9 and transposon terminal inverted repeats flanking a kanamycin resistance gene, were used to deliver Himar1 transposable element into the B. melitensis genome. Conjugation was performed efficiently and rapidly in less than one generation in order to minimize the formation of siblings while assuring the highest level of genome coverage.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17176467 PMCID: PMC1766931 DOI: 10.1186/1471-2180-6-102
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Fluorescence screen of . Preliminary screening was performed using J774.A1 macrophage-like cells that were infected with B. melitensis 16 M (panel A) or individual mutants (panels B, C, D) in 96-well microtiter dishes at MOI of 50, as described in Materials and Methods. Replication of each mutant was visualized using goat anti-B. melitensis and donkey-anti-goat IgG-Alexa Fluor 488. Images similar to those shown were captured using an Olympus IX70 inverted fluorescent microscope.
Himar 1 gene interruptions that attenuate survival of B. melitensis 16 M in J774.A1 macrophages assorted according to COG‡
| Genes Identified (#) | Fraction Identified (%) | Novel Genes (#) | Target Specificity† | ||
| Intracellular trafficking, secretion | II0025, II0026, II0027, II0028, II0029, | 11 | 12% | 3 | 12.8 |
| Nucleotide transport and metabolism | 10 | 11% | 5 | 3.5 | |
| Signal transduction | 5 | 5% | 3 | 2.4 | |
| Transcription | 13 | 14% | 11 | 2.1 | |
| Cell wall/membrane/envelope biogenesis | 15 | 16% | 7 | 1.9 | |
| Energy production and conversion | 8 | 8% | 2 | 1.2 | |
| Amino acid transport and metabolism | I0025, II0039, II0040, | 4 | 4% | 1 | 1.0 |
| Replication, recombination and repair | I0040, | 5 | 5% | 4 | 0.5 |
| Translation, ribosome structure and biogenesis | 3 | 3% | 3 | 0.4 | |
| Function unknown | 7 | 7% | 7 | 0.4 | |
| Posttranslational modification, protein turnover, chaperones | 3 | 3% | 2 | 0.4 | |
| Defense mechanisms | 1 | 1% | 1 | 0.3 | |
| General function prediction | 5 | 5% | 5 | 0.2 | |
| Carbohydrate transport and metabolism | 2 | 2% | 1 | 0.2 | |
| Lipid transport and metabolism | I1553 | 1 | 1% | 0.1 | |
| Coenzyme transport and metabolism | 1 | 1% | 1 | 0.1 |
‡ Genes assigned to COGs that are not listed were not identified.
* Numbers in bold reflect novel identification (n = 57). Those that are not bold have been identified previously using Tn5 by us and others [46]
/ Indicates intergenic insertion between two genes.
† ts or target specificity represents the ratio of insertions per COG divided by the fraction of the genome represented by that COG.
Summary of survival characteristics of novel attenuated mutants
| Intracellular trafficking, secretion, and vesicular transport | |||||||
| I | 1894 | Gramicidin S biosynthesis | grsT | S | -0.4 | 1.5 | 0.9 |
| II | 0029–30 | VirB5-B6 | virB5/6 | S | |||
| II | 0034 | Type IV secretion (channel protein) | virB10 | S | 2.5* | ||
| II | 0035 | Type IV secretion (ATPase) | virB11 | S | 2.3*** | ||
| Nucleotide transport and metabolism | |||||||
| I | 0233 | Phosphoribosylaminoimidazolecarboxamide formyltransfease | purH | S | 0.4 | 0.9 | |
| I | 0295 | Phosphoribosylaminoimidazole carboxylase ATPase subunit | purK | S | 0.3 | 0.9 | |
| I | 1123 | Phosphoribosylformylglycinamidine (FGAM) synthase | purS | S | 0.9 | 2.9 | |
| I | 1124 | Phosphoribosylformylglycinamidine (FGAM) synthase | purQ | S | 1.9 | 2.2 | |
| I | 1204 | Exopolyphosphatase (Ppx/GppA) | ppx | S | 0.4 | 1.2 | |
| Signal transduction mechanisms | |||||||
| I | 0066 | Response regulator (two component) | ompR | S | 0.6 | 1.3 | 1.9* |
| I | 1327 | Glutamate-ammonia-ligase adenylyltransferase (signal transduction) | glnE | S | -0.1 | 1.2 | 1.4 |
| I | 1807 | Universal stress protein | uspA | S | 0.4 | 0.1 | |
| Transcription | |||||||
| I | 0304/5 | Hypothetical thioesterase-transcriptional regulator | deoR | S | -0.5 | 1.9 | |
| I | 0371 | Regulatory factor (rpoE) | virF | S | -0.1 | 1.1 | 0.3 |
| I | 0508 | Transcription elongation factor | greA | S | 1.0 | 0.7 | 0.6 |
| I | 0513 | Transcription factor | lysR | S | 0.9 | ||
| I | 0513/4 | Transcription factor-hypothetical protein | lysR/hyp | S | 0.2 | 0.7 | |
| I | 0731/2 | Cold shock protein-hypothetical cytosolic protein | csp/hyp | S | 0.2 | 1.1 | 0.9 |
| I | 0808 | Transcriptional regulator (soxR) | merR | S | 1.0 | 0.8 | |
| I | 1178 | Transcriptional regulator (soxR) | merR | S | 0.0 | ||
| I | 1297/8 | RNA polymerase omega subunit-hypothetical protein | rpoZ/hyp | S | 0.2 | 1.3 | |
| I | 1364 | Transcriptional regulatory protein | mucR | S | 0.3 | 2.0*** | 3.0** |
| I | 1647/8 | Hyp-RegM (ATP-binding) | hyp/regM | S | 1.0 | -0.2 | |
| II | 1116/7 | Transcriptional activator LuxR-TetR families | luxR/tetR | S | 0.1 | 1.6** | 1.1 |
| Cell wall/membrane/envelope biogenesis | |||||||
| I | 0498/9 | Cold shock protein/soluble lytic transglycosylase | cspA/slt | R | 0.0 | 1.7*** | 2.9 |
| I | 1302 | Soluble lytic murein transglycosylase | mltE | R | 0.6 | 0.7 | 0.4 |
| I | 1415 | O-antigen export system permease protein | rfbD | R | 0.1 | 1.3 | |
| I | 1416 | O-antigen export system ATP-binding protein | rfbE | R | 0.3 | 1.9** | |
| I | 1427 | UDP-N-acetylglucosamine 4,6-dehydratase | capD | R | -0.3 | 1.4 | |
| II | 0380 | Acriflavin resistance protein A (membrane biogenesis) | acrA(hlyD) | S | 3.4 | ||
| II | 0472 | Membrane fusion protein (membrane biogenesis) | mtrC(hlyD) | S | 0.9 | 0.3 | |
| Energy production and conversion | |||||||
| I | 0972 | Glutathione reductase | gor | S | 0.3 | 0.5 | |
| I | 1749 | FAD-dependent glycerol phosphate dehydrogenase | glpD | S | 0.2 | 0.7 | |
| Amino acid transport and metabolism | |||||||
| II | 0285 | Dipeptide transport system (inner membrane permease) | dppB | S | 0.4 | 0.7 | |
| Replication, recombination and repair | |||||||
| I | 0334 | AAA ATPase/DNA helicase/DNA damage checkpoint | ruvB | S | 1.3 | 0.9 | |
| I | 1307 | Integrase/recombinase (phage) | xerC (int) | S | 0.1 | 1.1 | |
| I | 2023 | ATP-dependent nuclease subunit A | uvrD/rep | S | 0.9 | ||
| II | 0260 | GTP-binding protein | lepA | S | 0.9 | 0.1 | |
| I | 1296 | GTP-binding protein | lepA | S | 1.0 | ||
| Translation, ribosome structure and biogenesis | |||||||
| I | 0983 | Ribosomal large subunit pseudouridine synthase C | rluA | S | 0.5 | 1.1 | 1.0 |
| I | 1057 | Ribonuclease E/Zn metalloprotease | cafA | S | 0.5 | 1.1 | 1.6 |
| I | 1775–6 | Rnase PH-HrcA (heat shock protein repressor) | rph/hrcA | S | -0.2 | 1.0 | 0.6 |
| Function unknown | |||||||
| I | 0186 | Hypothetical cytosolic protein | dut | S | 0.6 | 0.4 | |
| I | 0193 | Hypothetical protein | hyp | S | 0.4 | 2.4 | 1.5 |
| I | 0490 | Hypothetical cytosolic protein | hycp | S | 0.6 | 0.6 | |
| I | 0540 | Hypothetical protein | hyp | S | 0.0 | 0.6 | |
| I | 0603 | Hypothetical protein | hyp | S | -0.1 | 1.1 | |
| I | 0732 | Hypothetical cytosolic protein | hycp | S | 1.4 | ||
| II | 0045–6 | Hypothetical protein-Hypothetical protein | hyp/hyp | S | |||
| Posttranslational modification, protein turnover and chaperones | |||||||
| I | 0816 | ATP-dependent clp protease ATP-binding subunit | clpA | S | 1.0 | 0.8 | 1.5 |
| II | 0932 | Glutaredoxin | nrdH | S | 1.1 | -0.3 | |
| Defense mechanisms | |||||||
| I | 0926 | Multidrug resistance locus | emrA | 2.2 | |||
| General function prediction | |||||||
| I | 1143 | Metal-dependent hydrolase (β-lactamase) | mbl | S | -0.1 | 0.9 | |
| I | 1282 | Glycine cleavage T protein (aminomethyltransferase) | gcvT | S | 1.2 | 0.4 | |
| I | 1487 | Colicin V production protein | colV | S | 1.2 | 0.5 | 0.8 |
| I | 1499 | Pirin (cupin) | pirA | S | -0.1 | 1.3 | 1.7 |
| I | 1867 | Florfenicol resistance protein | nifB/elp3 | S | 0.4 | 0.5 | |
| Carbohydrate transport and metabolism | |||||||
| I | 2031 | Phosphocarrier protein HPr | ptsH | S | -0.3 | 0.9 | 0.4 |
| II | 1095 | L-fuculose phosphate aldolase | sbgE | S | 0.7 | 2.2* | |
| Lipid transport and metabolism | |||||||
| Coenzyme transport and metabolism | |||||||
| I | 0657 | Outer membrane receptor (TonB-dependent transport) | btuB | S | 0.2 | 0.6 | |
a S v. R denotes smooth versus rough colony morphology
b In vitro growth: 1:1 mixtures of 16 M and select mutants used to inoculate culture to evaluate growth defects of the mutant. The output ratios are corrected for variance from the input ratios (approximately 1.0) and presented as a log10 value, also refrerred to as Δlog10. Macrophage survival is presented as a log10 of the ratio of recovery 16 M to mutant which may also be presented as Δlog10.
c Statistical analysis of macrophage and mouse splenic clearance revealed significant differences among means using 1-way ANOVA, Dunn's multiple comparisons using a non-attenuated mutant revealed statistically valid differences with p-values of 0.05 (*), 0.01 (**) and 0.001 (***).
d Mouse splenic clearance: 1:1 mixtures of 16 M and select mutants were used to inoculate mice i.p. to evaluate degree of in vivo attenuation of survival at one week.
/ Indicates intergenic insertion between two genes.
Figure 2Survival characteristics of novel and previously identified mutants validated in the mouse splenic clearance model of infection. To confirm attenuated virulence several of the mutants were evaluated for survival in the mouse splenic clearance model using a 1:1 mixture of parental wild-type (B. melitensis 16 M) and mutant to inoculate mice (n = 10 per group) with an overall dose of 5 × 106 cfu. At one (white bars) and four weeks (black bars) post inoculation spleens were excised from the mice, and recovery of the B. melitensis 16 M and the mutant were determined as described in the Materials and Methods. Recovery of Brucella is presented as a Survival Ratio (CFU 16 M/CFU mutant) corrected for variation in the input ratio in the inoculum calculated the same way.
Figure 3. The virulence of mutants interrupted in different genes of the erythritol locus were evaluated in the mouse splenic clearance model using mixtures (approximately 1:1) of B. melitensis 16 M and individual mutants containing interruptions in either eryB or eryC as indicated. Recovery of the parental wild-type and mutant were determined one week after infection by plating spleen homogenate on TSA with and without kanamycin as described in Materials and Methods. The ratio of wild-type to mutant recovered is corrected for variation in the input ratio and the final value is expressed as a ratio of 16 M to mutant recovered as described in Materials and Methods. The values shown reflect the ratios recovered plotted on a log scale. Differences in the average values were evaluated for significance via one-way ANOVA with Kruskal-Wallis test followed by Dunn's multiple comparisons between all groups p-value <0.0045 (**).